In a regulatory filing AMAG Pharmaceuticals (AMAG) disclosed that it has been made aware by Takeda Pharma (TKPYY), the exclusive product distributor of ferumoxytol in Switzerland, that it is recalling one specific batch of Rienso, ferumoxytol, from the Swiss market. This decision is based on a cluster of four post-marketing adverse event reports in Switzerland concerning hypersensitivity reactions of varying severity following the administration of Rienso from this batch. One of these cases included a report of a fatality. The batch was only distributed to and sold in Switzerland and the recall is limited to the specific batch and specifically Switzerland. Takeda Pharmaceutical Company Limited is also the exclusive distributor of this product in Canada and the European Union and Takeda Pharma AG is a wholly owned subsidiary of Takeda.